Neumora Therapeutics, Inc.
As of Oct 22, 2026, Neumora Therapeutics is in Stage 4, the downtrend phase, now in week 22 (since May 22, 2026). It closed at $0.41, 88.7% below its 52-week high and below its 200-day average, which is falling.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is NMRA early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
NMRA among Biotechnology463rd of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …463 | NMRA | Stage 4 · wk 22 | 12 | −44.5% |
Neumora Therapeutics: quick answers
What stage is Neumora Therapeutics in?
As of Oct 22, 2026, Neumora Therapeutics (NMRA) is in Stage 4, the downtrend phase. It entered Stage 4 on May 22, 2026 and is in week 22. What the four stages mean
Is Neumora Therapeutics in an uptrend?
No. Neumora Therapeutics is in a Stage 4 downtrend. It trades 77.9% below its 200-day average, which is falling.
How far is Neumora Therapeutics from its 52-week high?
Neumora Therapeutics closed at $0.41 on Oct 22, 2026, 88.7% below its 52-week high of $3.59. Its 52-week low is $0.36.
How has Neumora Therapeutics performed over the past year?
As of Oct 22, 2026, Neumora Therapeutics is down 77.4% over the past year and down 75.5% so far in 2026.
Which sector and industry is Neumora Therapeutics in?
Neumora Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company's preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson's Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.